* the change of sitSBP based on baseline between Treatment arm and control 1 arm \[ Time Frame: 8 weeks \] * the change of LDL-C based on baseline between Treatment arm and control2 arm \[ Time Frame: 8 weeks \]
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
237
co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg), Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg) and placebo of Olmetec Tab. 40mg(Olmesartan 40mg)
co-administration of Olmetec tab. 40mg(Olmesartan 40mg), Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg) and placebo of Sevikar tab. 10/40mg (Amlodipine/Olmesartan 10/40mg)
Yonsei University Health System, Severance Hospital
Seoul, South Korea
RECRUITINGthe change of MSSBP based on baseline between Treatment arm and control 1 arm
Time frame: 8 weeks
the change of LDL-C based on baseline between Treatment arm and control2 arm
Time frame: 8 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg, and placebo of Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg), Olmetec Tab. 40mg(Olmesartan 40mg)